Siemens Smart Infrastructure Chooses AWS as Its Preferred Cloud Provider for SAP Environments
Today, Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), announced that Siemens Smart Infrastructure, a business of the Siemens AG group focusing on energy distribution and intelligent buildings, is moving its SAP infrastructure to AWS. The business will migrate over 20 Enterprise Resource Planning (ERP) and Supply Chain Management (SCM) systems,based on SAP HANA, to AWS before the end of 2021. These systems support business-critical processes in areas such as manufacturing, operations, and sales across different business units including Building Products, Electrical Products, Digital Grid, and Distribution Systems. Moving these workloads to AWS will enable Siemens Smart Infrastructure to significantly shorten hardware refresh cycles, increase agility to test and deploy new systems, and provide the foundation for the company’s future transformation using SAP S/4HANA technology. This is the first migration of production-scale SAP systems to the cloud across the Siemens AG group, with Siemens Smart Infrastructure forecasting significant cost savings over the course of the next three years.
Siemens Smart Infrastructure’s migration of SAP to AWS is a core part of the company’s strategic plan to accelerate the modernization of their business. Working alongside AWS as their preferred cloud provider for SAP, Siemens Smart Infrastructure will be able to integrate their SAP environments with a wide range of advanced AWS technologies, in areas such as analytics and machine learning, to uncover new business value and drive innovation. All of this was not previously possible for Siemens Smart Infrastructure, as their SAP systems were siloed off from the rest of their business in co-located data centers. As the foundation of their new cloud-based SAP environment, Siemens Smart Infrastructure will utilize a broad range of AWS’s Amazon Elastic Compute Cloud (Amazon EC2) instances, including memory-optimized R5 instances for real-time big data analytics workloads, as well as X1 and X1e instances built for high-performance databases, in-memory databases, and other memory-intensive enterprise applications.
Siemens Smart Infrastructure and AWS started their successful collaboration five years ago, when Siemens began moving core parts of its digital building technology to the cloud. The company is currently using a number of other advanced AWS services including Amazon Aurora (a MySQL and PostgreSQL-compatible relational database built for the cloud), AWS Lambda (AWS’s serverless compute service), and Amazon Neptune (a fully managed graph database service).
“2020 has been a year like no other, yet AWS has been a dedicated and trustworthy partner on our digital transformation journey,” said Sébastien Bey, CIO of Siemens Smart Infrastructure. “Our SAP environments are the backbone of our organization; by moving these foundational pieces of the Siemens Smart Infrastructure business to AWS, we are not only reducing costs and upgrading the service we provide to our internal businesses, but also fundamentally changing the way we use technology to transform our business, innovate, and deliver value.”
“AWS is thrilled to be working alongside a forward-thinking and customer-centric business like Siemens Smart Infrastructure as they connect buildings and cities with their advanced technologies. AWS delivers proven performance, insights, and agility to advance Siemens Smart Infrastructure’s mission of helping customers around the world run their infrastructure in the most efficient and sustainable way and ensure our long-term future on this planet,” said Carla Stratfold, Vice President of AWS Global Verticals and Strategic Accounts at Amazon Web Services, Inc. “Organizations around the world trust their most essential SAP workloads to AWS because of our unmatched track record, breadth and depth of services, and vibrant partner community that helps them to transform their SAP landscapes.”
About Amazon Web Services
For 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 77 Availability Zones (AZs) within 24 geographic regions, with announced plans for 15 more Availability Zones and five more AWS Regions in India, Indonesia, Japan, Spain, and Switzerland. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are just some of the products and services pioneered by Amazon. For more information visit www.amazon.com/about and follow @AmazonNews.
About Siemens
Siemens Smart Infrastructure (SI)is shaping the market for intelligent, adaptive infrastructure for today and the future. It addresses the pressing challenges of urbanization and climate change by connecting energy systems, buildings and industries. SI provides customers with a comprehensive end-to-end portfolio from a single source – with products, systems, solutions and services from the point of power generation all the way to consumption. With an increasingly digitalized ecosystem, it helps customers thrive and communities progress while contributing toward protecting the planet. SI creates environments that care. Siemens Smart Infrastructure has its global headquarters in Zug, Switzerland, and has around 72,000 employees worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005094/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom